Showing papers in "Drug Discovery Today in 2017"

TL;DR: Zinc oxide NPs have been successfully exploited as drug carriers for loading and transporting drugs to target sites, thereby reducing unwanted toxicity and off-target effects, and resulting in amplified synergistic effects.

TL;DR: The history of machine learning is summarized and insight into recently developed deep learning approaches and their applications in rational drug discovery are provided to help guide early-stage drug design and discovery in the current big data era.

TL;DR: An overview of the 1,2,3-triazole ring as a bioisostere for the design of drug analogs, highlighting relevant recent examples.

TL;DR: A comprehensive review on PECs and their classification, theory and characterization, as well as a critical analysis of the current research are provided.

TL;DR: This review focuses on the description and the clinical benefits of different DOX-loaded nanotechnological platforms, not only those commercially available but also the ones that are currently in clinical phases, such as liposomes, polymeric nanoparticles, polymer-drug conjugates,polymeric micelles and ligand-based DOX -loaded nanoformulations.

TL;DR: The biomedical applications of graphene-based nanomaterials (GBNs) are discussed, including drug and/or gene delivery, bioimaging, and tissue engineering, and their unique properties related to their biomedical applications are discussed.

TL;DR: How the applications of MD approaches are significantly transforming current drug discovery and development efforts is discussed.

TL;DR: The development of miRNA nanoformulations are focused on to achieve enhanced cellular uptake, bioavailability, and accumulation at the tumor site to reduce the required therapeutic dosage while minimizing systemic and cellular toxicity.

TL;DR: This review provides an account of various types of MOFs, their physiochemical characteristics and use in diverse disciplines of biomedical sciences - with special emphasis on drug delivery and theranostics, along with their market potential for biomedical applications.

TL;DR: Findings highlight the importance of using appropriate model systems and identifying target patient groups as potential therapies advance into the clinic, and the need to develop drugs that target metabolic dependencies.

TL;DR: A variety of chemical modifications, including l to d isomerization, cyclization, and unnatural amino acid substitution, as well as design strategies, such as attachment to cell-penetrating peptides, which are used to develop peptidomimetics are discussed.

TL;DR: The objectives were to assess factors that could contribute to the specific toxicities observed with these two classes of promising drugs, and get a better understanding of the potential mechanism(s) responsible for these rare, but serious, adverse events.

TL;DR: This review highlights recent advances in the delivery of anticancer drugs using dendrimers, as well as other biomedical and diagnostic applications that have a significant positive impact on the growing arena of drug delivery and targeting.

TL;DR: Different topical formulations of curcumin are discussed with emphasis on their wound-healing properties in animal models to discuss their potential for wound healing in humans.

TL;DR: Available mouse models of NASH address different aspects of the disease, have varying clinical translatability, and, therefore, also show different utility in drug discovery.

TL;DR: In this review, the contributions of the Kinetics for Drug Discovery (K4DD) Consortium are highlighted, which targets major open questions related to binding kinetics in an industry-driven public-private partnership.

TL;DR: In vitro and in vivo experiments have repeatedly indicated HA-based nanocarriers to be a target-specific drug and gene delivery platform with great promise for future applications in clinical cancer therapy.

TL;DR: The present review focuses on recent approaches for colon-specific drug delivery (CDDS) and aims to unveil the emerging possibilities and advances in the treatment of CC with CDDS.

TL;DR: Principal Component Analysis is a 'hypothesis generating' tool creating a statistical mechanics frame for biological systems modeling without the need for strong a priori theoretical assumptions.

TL;DR: The in vitro assays currently available have shown poor translational outcomes, with high compound attrition rates, so it is imperative that more physiologically relevant assays are developed to identify anti-leishmanial compounds.

TL;DR: The mechanisms by which cellular senescence can promote aging are summarized, and an extensive description of current potential pharmacological interventions for senescent cells is offered, highlighting limitations and suggesting alternatives.

TL;DR: An overview of macrophage functional diversity during various diseases, including infection, as well as the current status in the development and clinical utility of epigenetic modifiers are provided.

TL;DR: Recent advances in the development of novel AMPs with improved antimicrobial activities that were achieved through characteristic structural design are outlined and progress made to overcome some of the major limitations that have hindered peptide biosynthesis are described.

TL;DR: This work provides a comprehensive overview of the current status of in silico repurposing methods by establishing links between current technological trends, data availability and characteristics of the algorithms used in these methods.

TL;DR: Novel EP receptor subtype selective agonists and antagonists appear to be valuable drug candidates in the therapy of many pathophysiological states, including ulcerative colitis, glaucoma, bone healing, B cell lymphoma, neurological diseases, among others.

TL;DR: This review of the latest studies regarding the role of the ECS and the drugs that target it highlights the creation of a cannabinoid-receptor interaction matrix (CRIM) and the use of metabolomics toward the development of improved and more specific drugs for each relevant disease.

TL;DR: With advances in bioengineering, linker chemistry, and potent cytotoxic payload, ADC technology has become a more powerful tool for targeted cancer therapy and ADCs with improved safety using humanized Abs with a unified 'drug:antibody ratio' (DAR) have been achieved.

TL;DR: The available literature is discussed, highlighting the 3D architecture and preparation of these nanoscaffolds, and also challenges to, and advances in, the use dendrimers in tissue engineering are reviewed.

TL;DR: It is assumed that such emerging hybrid nanosystems - from combining two already-established drug delivery platforms - could lead the way for the development of newer delivery systems with multiple applicability for latent theranostic applications in the future.

TL;DR: This review provides an overview of recently developed polymer-coated multifunctional SPIO nanoparticles for cancer theranostics and discusses current challenges and future perspectives.